Several other equities analysts have also recently weighed in on the stock. Royal Bank of Canada reiterated a buy rating and set a $22.00 price objective on shares of ObsEva in a research report on Thursday, November 2nd. Zacks Investment Research upgraded shares of ObsEva from a sell rating to a hold rating in a research report on Friday, September 8th. Credit Suisse Group assumed coverage on shares of ObsEva in a research report on Monday, October 9th. They set an outperform rating and a $16.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on shares of ObsEva in a research report on Monday, December 4th. They set an outperform rating and a $20.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. ObsEva has an average rating of Buy and a consensus price target of $19.00.
ObsEva (NASDAQ OBSV) remained flat at $$9.83 during trading on Thursday. The company had a trading volume of 8,500 shares, compared to its average volume of 14,567. The stock has a market cap of $371.31 and a price-to-earnings ratio of -4.51. ObsEva has a 1-year low of $5.00 and a 1-year high of $14.69.
ObsEva (NASDAQ:OBSV) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.01). ObsEva’s revenue for the quarter was up NaN% compared to the same quarter last year. sell-side analysts forecast that ObsEva will post -2.31 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Iguana Healthcare Management LLC grew its position in ObsEva by 66.7% during the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after purchasing an additional 20,000 shares in the last quarter. VHCP Management II LLC purchased a new position in ObsEva during the 2nd quarter worth approximately $1,283,000. Sectoral Asset Management Inc grew its position in ObsEva by 181.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after purchasing an additional 137,331 shares in the last quarter. Sphera Funds Management LTD. grew its holdings in shares of ObsEva by 12.4% during the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock valued at $2,118,000 after acquiring an additional 28,700 shares in the last quarter. Finally, Abingworth LLP purchased a new position in shares of ObsEva during the 3rd quarter valued at $3,480,000. Hedge funds and other institutional investors own 35.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ObsEva (OBSV) Given a $25.00 Price Target at HC Wainwright” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://transcriptdaily.com/2018/01/05/obseva-obsv-given-a-25-00-price-target-at-hc-wainwright.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.